AQUIPTA® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1
ONCE-DAILY TABLET1 THAT IS EASY TO TAKE2
Dose modification
10 mg once daily is recommended in patients:1
- Taking concomitant strong organic anion transporting polypeptide (OATP) inhibitors
- Taking concomitant strong cytochrome P450 3A4 (CYP3A4) inhibitors
- With severe renal impairment (creatinine clearance [CrCl] 15–29 mL/min), or end-stage renal disease (CrCl <15 mL/min)
- For patients with end-stage renal disease undergoing intermittent dialysis, AQUIPTA™ should preferably be taken after dialysis
Tablet not actual size.
Taken once daily1
Tablet should be swallowed whole, should not be split, crushed or chewed1
Tablet not actual size.
No special storage conditions1
Tablet not actual size.
Taken with or without food1
Tablet not actual size.
Half-life: approximately 11 hours1
References:
1. AQUIPTA® Summary of Product Characteristics (Ireland). 2. Raja A, et al. Front Neurol. 2024 Sep 27:15:1468961.
IE-AQP-250021 Date of Preparation: October 2025
